Technology
Health
Pharmaceutical

Crinetics Pharmaceuticals

$24.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.44 (1.82%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CRNX and other stocks, options, ETFs, and crypto commission-free!

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. Read More It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Employees
49
Headquarters
San Diego, California
Founded
2008
Market Cap
582.38M
Price-Earnings Ratio
Dividend Yield
Average Volume
89.19K
High Today
$24.97
Low Today
$24.00
Open Price
$24.01
Volume
21.28K
52 Week High
$42.00
52 Week Low
$19.23

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
2018 IPO
US
North America

CRNX Earnings

-$0.41
-$0.39
-$0.37
-$0.35
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 13, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.